Series A generates $9.6mm for Arsanis
Start-up infectious disease firm Arsanis Inc. brought in $9.6mm via its Series A equity financing to Polaris Venture Partners, SV Life Sciences, OrbiMed Advisors--each contributes one board member--and four undisclosed backers.
- Large Molecule
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com